Aurobindo Pharma recently gained approval from the Food and Drug Administration for its hydromorphone HCI tablets.
Hydromorphone tablets are intended to relieve moderate to severe acute pain in patients when opioid use is necessary and appropriate.
The tablets are a generic version of Stamford, Conn.-based Purdue Pharma's Dilaudid tablets.
The India-based drug company's new tablets represent the 12th approved treatment developed by its Dayton, N.J.-based subsidiary Aurolife.
More articles on the drug market:
Drug shortages force workarounds in Conn. hospitals
4 reasons adults need vaccines just as much as kids
Drugmakers have firm grasp on drug pricing power